Structured in three pillars
The TheraVision project is establishing a broadly applicable platform technology for combinatorial oncolytic virus-immunotherapy based on three pillars.
1 Engineering of therapeutic virus vectors
An HSV1 platform vector was established by genetic engineering and in the next step will be functionalized as an oncolytic virus with not only high specificity by means of viral targeting to cancer cells but also high efficacy by encoding immune modulators.
2 Virus manufacturing using a robust and scalable process
For the manufacturing of such a virus, a robust and scalable process is being developed, optimized by bioinformatic modeling. This process addresses the regulatory stipulations of Good Manufacturing Practice (GMP) to allow for a seamless transfer to GMP manufacturing.
3 Testing using novel and meaningful preclinical in vitro and in vivo models
For preclinical validation of the therapeutic viruses, a broad range of new models are being established to enable investigation of the therapeutic effects of these viruses on primary tumors and metastases in the presence of human immune cells. These include human 3D in vitro tumor models as well as complex humanized in vivo mouse models.
As proof of concept, an oncolytic virus for treating non-small-cell lung cancer (NSCLC) is being developed.